Scholars@Duke
Nelson Jen An Chao

Nelson Jen An Chao

Donald D. and Elizabeth G. Cooke Cancer Distinguished Research Professor
Medicine, Hematologic Malignancies and Cellular Therapy
nelson.chao@duke.edu
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710

Scholarly Works - Conferences

Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.

Conference Bone Marrow Transplant · January 2022 Hematopoietic cell transplant (HCT) is an increasingly common and curative treatment strategy to improve survival among individuals with malignant and nonmalignant diseases, with over one million HCTs having been performed worldwide. Neurocognitive dysfunc ... Full text Link to item Cite

Impact of a pilot patient navigator program on pediatric cancer outcomes in a low resource setting.

Conference Journal of Clinical Oncology · May 20, 2019 e18152 Background: Oncology patient navigation programs have been successfully implemented at hospitals throughout the U.S., enhancing the quality of canceer care. In low resource settings, the barriers to receiving cancer care a ... Full text Cite

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Conference Biol Blood Marrow Transplant · November 2017 Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation ( ... Full text Link to item Cite

Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.

Conference Journal of Clinical Oncology · May 20, 2017 8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m2bendamustine/3mg pomali ... Full text Cite

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.

Conference Adv Radiat Oncol · 2016 PURPOSE: The purpose of this study was to compare leukemia-free survival (LFS) and other clinical outcomes in patients with acute myelogenous leukemia who underwent a myeloablative allogeneic stem cell transplant with and without total body irradiation (TB ... Full text Open Access Link to item Cite

Long Term Survival Following High-dose Sequential Therapy with Autologous Hematopoietic Cell Rescue for Multiple Myeloma

Conference · 2010 High-dose therapy (HDT) with autologous hematopoietic cell rescue (AHCR) improves survival in patients with multiple myeloma, but is not curative due to a continuous risk of relapse. One approach to try to reduce relapse is to optimize the pretransplant t ... Cite

Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants

Conference Blood · December 1, 2000 Non-myeloablative allogeneic peripheral blood stem cell transplants {mini-allo PBSCT) are being evaluated as a lower toxicity alternative to conventional allogeneic transplantation for harnessing graft versus tumor effects. Induction of anti-tumor immunity ... Cite